Carna Biosciences Inc
TSE:4572
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Carna Biosciences Inc
Income from Continuing Operations
Carna Biosciences Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carna Biosciences Inc
TSE:4572
|
Income from Continuing Operations
-¥2.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Income from Continuing Operations
¥3.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Medinet Co Ltd
TSE:2370
|
Income from Continuing Operations
-¥1.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
3%
|
|
|
CellSource Co Ltd
TSE:4880
|
Income from Continuing Operations
¥89.7m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Income from Continuing Operations
¥363.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
Income from Continuing Operations
-¥58.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
Carna Biosciences Inc
Glance View
Carna Biosciences, Inc. engages in the drug discovery business. The company is headquartered in Kobe, Hyogo-Ken and currently employs 64 full-time employees. The company went IPO on 2008-03-25. The firm operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
See Also
What is Carna Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
-2.2B
JPY
Based on the financial report for Dec 31, 2025, Carna Biosciences Inc's Income from Continuing Operations amounts to -2.2B JPY.
What is Carna Biosciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-14%
Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Carna Biosciences Inc have been -17% over the past three years , -14% over the past five years .
